324 related articles for article (PubMed ID: 30058011)
1. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
Padula WV; Ballreich J; Anderson GF
Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
[TBL] [Abstract][Full Text] [Related]
2. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
3. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
5. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
Dusetzina SB; Conti RM; Yu NL; Bach PB
JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
[No Abstract] [Full Text] [Related]
8. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
9. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
[TBL] [Abstract][Full Text] [Related]
10. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
Davis MM; Patel MS; Halasyamani LK
J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
[TBL] [Abstract][Full Text] [Related]
11. Cost minimization of medicare part D prescription drug plan expenditures.
Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
[TBL] [Abstract][Full Text] [Related]
12. Beneficiary price sensitivity in the Medicare prescription drug plan market.
Frakt AB; Pizer SD
Health Econ; 2010 Jan; 19(1):88-100. PubMed ID: 19191252
[TBL] [Abstract][Full Text] [Related]
13. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
14. Potential opportunity cost of neglecting to annually reassess Medicare Part D standalone prescription drug plan offerings: the price of contentment?
Walberg MP; Patel RA
J Am Pharm Assoc (2003); 2009; 49(6):777-82. PubMed ID: 19926558
[TBL] [Abstract][Full Text] [Related]
15. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
[TBL] [Abstract][Full Text] [Related]
16. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
[TBL] [Abstract][Full Text] [Related]
17. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
18. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
19. Effects of an out-of-pocket maximum in Medicare Part D.
Parasrampuria S; Anderson GF
Am J Manag Care; 2022 Feb; 28(2):e55-e62. PubMed ID: 35139297
[TBL] [Abstract][Full Text] [Related]
20. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
Dusetzina SB; Keating NL
J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
